Breaking Finance News

UnitedHealth (NYSE:UNH) target bumped up to $178.00, released a research note earlier today by Mizuho Securities

Mizuho Securities bumped up the target of UnitedHealth (NYSE:UNH) to $178.00 stating a potential upside of 0.13%.

Showing a price of $157.59, UnitedHealth (NYSE:UNH) traded 3.60% higher on the day. The last stock price is up 12.22% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.03% over the same period. UnitedHealth has recorded a 50-day average of $143.81 and a two hundred day average of $139.88. Trade Volume was up over the average, with 5,827,585 shares of UNH changing hands over the typical 3,746,020

Recent Performance Chart

UnitedHealth (NYSE:UNH)

UnitedHealth has price-earnings ratio of 23.19 with a one year low of $107.51 and a one year high of $158.12 and has a total market value of $0.

A total of 24 equity analysts have released a ratings update on UNH. 10 brokers rating the stock a strong buy, 12 brokers rating the stock a buy, 3 brokers rating the stock a hold, 1 broker rating the stock a underperform, and finally 0 brokers rating the stock a sell with a average stock price target of $144.17.

General Information About UnitedHealth (NYSE:UNH)

UnitedHealth Group Incorporated is a diversified healthcare company. The Company operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight and OptumRx. The Company conducts its operations through two business platforms: health benefits operating under UnitedHealthcare and health services operating under Optum. UnitedHealthcare provides healthcare benefits to a range of customers and markets through its UnitedHealthcare Employer & Individual, UnitedHealthcare Medicare & Retirement, UnitedHealthcare Community & State, and UnitedHealthcare Global businesses. Optum is a health services business serving the healthcare marketplace, including payers, care providers, employers, governments, life sciences companies and consumers, through its OptumHealth, OptumInsight and OptumRx businesses.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *